4.0 Clinical Evaluation Prior to Treatment 
As described above, patients will be selected based on their 
past medical history and clinical course. Patients must have 
histologically confirmed metastic melanoma which is unresponsive 
to standard curative or palliative measures. Patients with 
expected survival times of 1 year or less will be chosen. The 
patients must meet the standard inclusion and exclusion criteria 
described above. In addition, the chosen patients must show no 
signs of active systemic infection or major cardiovascular or 
respiratory disease. The following laboratory values will be 
used as guidelines as enrollment: 
1. The bilirubin should be less than 2 mg/dl. The 
platelet count should be greater than 100,000/mm 3 . 
The white blood cell count should exceed 3,000/mm . 
The creatinine should be less than 2.0 mg/dl. 
2. HLA typing must indicate that the patient is HLA-B7 
negative. 
3. HIV antibody titers will be measured. 
[7101 
Recombinant DNA Research, Volume 17 
